Abstract
This is a report on 14 patients receiving vindesine continuously for between 1 and 7 years. Total vindesine doses ranged from 86 mg to 454 mg and the longest treatment duration was 2564 days. Although there was no patient without a transient acute or subacute toxicity, no unequivocal signs of long-term toxicity have been observed so far. Greater caution must be given to the concomitant use of higher radiation doses and vindesine, since local reactions were more pronounced especially at the lung. The drug seems to be tolerated for longer periods without major or cumulative toxicity, which makes it suitable for use in the adjuvant setting, for instance, or within an antimetastatic approach.
Key words: Vindesine, Long-term application, Toxicity
References
- Atassi G, Dumont P, Vandendris M (1982) Investigation of the in vivo anti-invasive and anti-metastatic effect of desacetyl vinblastine amide sulphate or vindesine. Invasion Metastasis 2:217–231 [PubMed] [Google Scholar]
- Dyke RW, Nelson RL (1977) Phase I anti-cancer agents, vindesine. Cancer Treat Rev 4:135–142 [DOI] [PubMed] [Google Scholar]
- Huntington MO (1985) Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast. Cancer 56:472–474 [DOI] [PubMed] [Google Scholar]
- Knobf MK, Mullen JC, Xistris D, Moritz DA (1983) Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nursing Forum 10:28–33 [PubMed] [Google Scholar]
- Mareel MM, De Mets W (1984) Effect of microtubule inhibitors on invasion and related activities of tumor cells. Int Rev Cytol 90:125–168 [DOI] [PubMed] [Google Scholar]
- Rhomberg WU (1986) Vindesine for recurrent and metastatic cancer of the uterine cervix, a phase II study. Cancer Treat Rep 10:1455–1457 [PubMed] [Google Scholar]
- Storme G, Schallier D, De Neve W, De Greve J, Van Belle S, Dewasch G, Dotremont G (1985) In: Hellmann K, Eccles SA (eds) Prevention of metastasis, problems and prospects, Taylor & Francis, London, pp 25–28 [Google Scholar]